ImmunityBio, Inc. Common Stock (IBRX) Stock Price

IBRXStock

$8.19+228.14%52W

Market Cap$8.68B

P/E—

PEG Ratio—

Div yield—

Beta0.07

IBRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-22.49%

Price vs S&P 500 (4W)5.70%

VGM Score54.89

Book Value / Share (Quarterly)$1.37

P/TBV (Annual)3.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)678.62%

Cash Flow / Share (Quarterly)$-0.27

Price vs S&P 500 (YTD)270.87%

Gross Margin (TTM)99.34%

Net Profit Margin (TTM)-598.56%

EPS (TTM)$-0.97

10-Day Avg Trading Volume6.80M

EPS Excl Extra (TTM)$-0.97

Revenue Growth (5Y)184.30%

EPS (Annual)$-0.38

ROI (Annual)-129.86%

Gross Margin (Annual)99.34%

Net Profit Margin (5Y Avg)-61547.29%

Cash / Share (Quarterly)$0.34

Revenue Growth QoQ (YoY)93.91%

ROA (Last FY)-70.01%

Revenue Growth TTM (YoY)192.92%

EBITD / Share (TTM)$-0.24

ROE (5Y Avg)-69.68%

Operating Margin (TTM)-151.88%

Cash Flow / Share (Annual)$-0.31

P/B Ratio54.60x

P/B Ratio (Quarterly)5.04x

Net Income / Employee (Annual)$-508,500

EV / Revenue (TTM)55.65x

Net Interest Coverage (TTM)-1.40x

ROA (TTM)-172.88%

EPS Incl Extra (Annual)$-0.38

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)5.36x

3-Month Avg Trading Volume11.92M

52-Week Price Return228.14%

Revenue / Employee (TTM)$239,900

Tangible BV / Share (Quarterly)$1.23

P/S Ratio (Annual)71.61x

Asset Turnover (Annual)0.23x

52-Week High$12.43

Operating Margin (5Y Avg)-48537.75%

EPS Excl Extra (Annual)$-0.38

CapEx CAGR (5Y)20.55%

26-Week Price Return-11.24%

Quick Ratio (Annual)4.62x

13-Week Price Return-2.07%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.72x

Enterprise Value$9.23B

Revenue / Share Growth (5Y)138.40%

Asset Turnover (TTM)0.29x

Revenue / Employee (Annual)$163,900

Pretax Margin (Annual)-310.37%

Cash / Share (Annual)$0.24

3-Month Return Std Dev64.59%

Net Income / Employee (TTM)$-1,436,100

ROE (Last FY)-130.72%

Net Interest Coverage (Annual)-1.24x

EPS Basic Excl Extra (Annual)$-0.38

Receivables Turnover (TTM)4.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.97

Receivables Turnover (Annual)5.04x

ROI (TTM)-193.00%

P/S Ratio (TTM)48.94x

Pretax Margin (5Y Avg)-61695.41%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$1.23

Price vs S&P 500 (52W)209.83%

Year-to-Date Return282.83%

5-Day Price Return-1.81%

EPS Normalized (Annual)$-0.38

ROA (5Y Avg)-96.51%

Net Profit Margin (Annual)-310.18%

Month-to-Date Return5.72%

Cash Flow / Share (TTM)$-1.09

EBITD / Share (Annual)$-0.26

Operating Margin (Annual)-226.00%

ROI (5Y Avg)-68.78%

EPS Basic Excl Extra (TTM)$-0.97

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)3.09x

Inventory Turnover (TTM)0.26x

Pretax Margin (TTM)-598.69%

Book Value / Share (Annual)$1.23

Price vs S&P 500 (13W)-4.86%

Beta0.07x

Revenue / Share (TTM)$0.16

ROE (TTM)-193.29%

52-Week Low$1.95

vGradeF

gGradeA

mGradeC

vgmGradeC

IBRX Earnings Surprise History

Q2 25-0.10est. -0.10

Q3 25-0.07est. -0.10

Q4 25-0.06est. -0.10

Q1 26-0.08est. -0.07

Q2 26-0.22est. -0.08

IBRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

4.30

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About ImmunityBio, Inc. Common Stock

ImmunityBio develops immunotherapies for cancer and infectious diseases through its proprietary Cancer BioShield platform, which activates both adaptive and innate immune systems. The platform is anchored by ANKTIVA, an IL-15 superagonist, complemented by adenovirus-vectored vaccines and NK-cell therapies. The company generates the majority of its revenue in the United States, with additional operations in Europe.